Children with cancer receiving immunosuppressive therapy are vulnerable to severe pneumococcal disease (IPD). This thesis examines the role of the 13-valent pneumococcal conjugate vaccine (PCV13) in children undergoing (AIT) or recently completed immunosuppressive cancer therapy (CIT) to prevent and reduce IPD. A prospective, open-label cohort study included children with cancer given a dose of PCV13 demonstrated satisfactory immunogenic responses and low rate of serious adverse events. Our study design was suboptimal to evaluate vaccination and its role for preventing nasopharyngeal colonization.
|Award date||28 Aug 2018|
|Publication status||Unpublished - 2018|